MI-LINEAGE-LOGISTICS-LLC
11.1.2022 08:03:03 CET | Business Wire | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today announced the acquisitions of Van Tuyl Logistics, H&S Coldstores and Frigocare Rotterdam BV. These strategic transactions will strengthen Lineage’s portfolio of end-to-end logistics solutions in the region and grow Lineage’s presence in the Netherlands by more than 250,000 cubic metres of capacity.
Based in Gameren, Van Tuyl Logistics is a Dutch provider of temperature-controlled logistics that specialises in refrigerated and frozen transport. Van Tuyl employs a modern fleet of 60 trucks and 90 trailers with a self-owned repair station, in addition to warehousing services for 30,000 pallet spaces at different temperatures and a real estate holding division.
“We are pleased to welcome Van Tuyl Logistics into the One Lineage Family as we continue to build momentum and further expand our European operations,” said Harld Peters, Senior Vice President, Europe at Lineage. “The Netherlands remains a critical hub for the food cold chain within the European market, given its central location and accessibility to key seaports and inland terminals. Accordingly, the addition of Van Tuyl will help Lineage to connect more points across our customers’ extended supply chains.”
“We know that Lineage is the right partner for the next stage in our company’s history and in our ambition to reimagine the journey of food,” said Richard van Tuijl, General Director of Van Tuyl Logistics. “Our end-to-end solutions complement Lineage’s strong and growing presence in Europe, and we are confident that our customers will continue to be well-served as we combine our logistics and cold storage operations.”
Lineage also acquired Dutch provider H&S Coldstores and its logistics forwarding business from the H&S Group, Europe’s largest intermodal Liquid Food operator.
Headquartered in Beneden-Leeuwen, H&S Coldstores provides end-to-end juice supply chain services, including transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions. The logistics forwarding business from H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles as well as more than 1,500 tank units for the liquid foodstuff industry.
In total, this acquisition will add a capacity of 48,000 tonnes to Lineage’s footprint in Europe. The H&S Coldstores facilities in Elst and Tiel will be moved to a new location in a newly built facility, closer to other existing facilities in Beneden-Leeuwen. This new cold store near the port of Rotterdam will be operational by mid-2022. This new facility complies with the highest LEED/BREEAM status and will make use of solar energy.
“H&S Coldstores is another fantastic example of our continued investment in the Netherlands,” said Peters of Lineage. “In particular, their differentiated juice-blending services greatly complement our existing capabilities via our recent acquisition of Kloosterboer, and will further diversify our business offering across the cold chain.”
Finally, Lineage also announced today the acquisition of the Dutch facilities of Frigocare Rotterdam BV, a company specialized in handling imports of frozen fish mainly from the North Atlantic and Asia to the Port of Rotterdam. The facility is located near an existing Lineage facility in the same harbour and will add 15,000 pallet positions in its 20,000 square metre warehouses to Lineage’s operations in Rotterdam.
Financial terms of the transactions were not disclosed.
About Lineage Logistics
Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 19 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com )
About Van Tuyl Logistics
Van Tuyl Logistics is a Dutch cold chain logistics company, active in The Netherlands since its inception in 1983. The company specialises in refrigerated and frozen transport of fresh produce and other foodstuffs. Aside from its transport activities, Van Tuyl Logistics also provides storage solutions via their cold storage facility, located in Gameren, The Netherlands.
About H&S Group
H&S Group is Europe’s largest intermodal Liquid Food operator. The company is headquartered in Barneveld, The Netherlands and provides end-to-end supply chain services. H&S Group also offers a pan-European network of more than 250 privately owned and subcontracted vehicles, and more than 1,500 tank units for the liquid foodstuff industry. H&S Coldstores owns three facilities in Tiel, Beneden-Leeuwen and Elst, where it provides the following services: transport, warehousing, customs, production, processing, laboratory testing, and packaging solutions.
About Frigocare Rotterdam
Frigocare Rotterdam BV is a cold store company specialised in food logistics, specifically handling frozen fish from the North Atlantic and Asia to the port of Rotterdam, The Netherlands. The company provides the following services aside from storage: container reception, border inspection, sorting, palletizing, (re)packing and (un)loading of various delicate cargo, mostly seafood, under EU-license.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110006028/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom